Significance of CD 105 expression for tumour angiogenesis and prognosis in endometrial carcinomas.
Angiogenesis is a key process in tumour growth and metastasis, and Factor-VIII microvascular density has been found to influence prognosis among endometrial carcinoma patients. The CD105/endoglin antibody has been reported to preferentially bind to activated endothelial cells in tissues participating in angiogenesis, and we therefore wanted to compare the prognostic significance of CD105/endoglin to that of Factor-VIII. In a population-based endometrial carcinoma study with long (median 11.5 years) and complete patient follow-up, mean intratumour microvascular density (MVD) assessed using CD105/endoglin was investigated and compared with previous data for MVD assessed using Factor-VIII. MVD by CD105/endoglin was significantly correlated with MVD by Factor-VIII (p=0.001). However, tumours within the two groups defined by the upper and lower quartiles for CD105/endoglin-MVD were both significantly more often metastatic (FIGO-stage III/IV; p=0.03), with high tumour cell proliferation by Ki67 (p=0.007) and with reduced survival (p=0.036) as compared with the intermediate groups. In Cox regression analysis, CD105/endoglin-MVD showed independent prognostic influence when analysed together with patient age, FIGO stage, histologic subtype, histologic grade and Factor-VIII-MVD, while the latter lost its prognostic impact when CD105/endoglin was included. In the subgroup with high MVD, there was a tendency towards improved response to radiation therapy. In conclusion, CD105/endoglin-MVD is significantly associated with FIGO stage, tumour proliferation and prognosis in endometrial carcinoma, indicating that this is a better angiogenic marker in these tumours.
Salvesen
Helga B
HB
Department of Pathology, The Gade Institute, Bergen, Norway. helga.salvesen@haukeland.no
Gulluoglu
Mine G
MG
Stefansson
Ingunn
I
Akslen
Lars A
LA
D015703:Antigens, CD; D014408:Biomarkers, Tumor / Q000032:analysis* / Q000378:metabolism; D018269:Carcinoma, Endometrioid / Q000098:blood supply* / Q000473:pathology / Q000532:radiotherapy; D000071063:Endoglin; D016889:Endometrial Neoplasms / Q000098:blood supply* / Q000473:pathology / Q000532:radiotherapy; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007150:Immunohistochemistry; D008833:Microcirculation / Q000378:metabolism / Q000473:pathology; D009367:Neoplasm Staging; D009389:Neovascularization, Pathologic / Q000378:metabolism* / Q000473:pathology; D009664:Norway; D011379:Prognosis; D011956:Receptors, Cell Surface; D012044:Regression Analysis; D012189:Retrospective Studies; D015996:Survival Rate; D019010:Vascular Cell Adhesion Molecule-1 / Q000032:analysis* / Q000378:metabolism
D015703:Antigens, CD; D014408:Biomarkers, Tumor; C064206:ENG protein, human; D000071063:Endoglin; D011956:Receptors, Cell Surface; D019010:Vascular Cell Adhesion Molecule-1